| epirubicin / Generic mfg. |
NCT00008034: Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer |
|
|
| Completed | 1 | 15 | Europe | capecitabine, cyclophosphamide, epirubicin hydrochloride | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 12/00 | | | |
NCT00364754: Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer |
|
|
| Completed | 1 | 28 | RoW | Tesmilifene (YMB 1002) | YM BioSciences | Metastatic/Recurrent Breast Cancer | 01/06 | 01/06 | | |
NCT00753207: Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 |
|
|
| Completed | 1 | 10 | Europe | epirubicin hydrochloride, lapatinib ditosylate, biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry | Cancer Trials Ireland | Breast Cancer | 11/08 | 03/12 | | |
| Completed | 1 | 42 | Europe | Ixabepilone, IXEMPRA®, BMS-247550, Epothilone, Epirubicin | R-Pharm | Metastatic Breast Cancer | 02/09 | 02/09 | | |
CYBERNEO, NCT00872625: Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer |
|
|
| Completed | 1 | 26 | Europe | cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy, image-guided radiation therapy, radiation therapy, stereotactic radiosurgery | Centre Antoine Lacassagne | Breast Cancer | 04/09 | 12/10 | | |
NCT00722293: A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors |
|
|
| Completed | 1 | 111 | Europe | Doxorubicin, Pazopanib (GW786034), Epirubicin | GlaxoSmithKline | Neoplasms, Breast | 06/12 | 02/14 | | |
NCT01624441: Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Completed | 1 | 40 | US | Dinaciclib, CDK Inhibitor SCH 727965, MK-7965, SCH 727965, Epirubicin Hydrochloride, Ellence, IMI-28, Pharmorubicin PFS, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma | 09/13 | 09/13 | | |
|
